3461 - 3470 of 6420 Results
Title
Year
-
OPENTitle: Plasma NfL, clinical subtypes and motor progression in Parkinson's diseaseJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 87Issue #:Start Page: 41End Page: 47Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.04.016Citation Count: 45
-
OPENTitle: Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patientsJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 87Issue #:Start Page: 25End Page: 31Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.04.012Best OA location URL: http://www.prd-journal.com/article/S1353802021001450/pdfCitation Count: 19
-
OPENTitle: Exploratory analysis of the genetics of impulse control disorders in Parkinson's disease using genetic risk scoresJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 86Issue #:Start Page: 74End Page: 77Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.04.003Best OA location URL: https://hal.archives-ouvertes.fr/hal-03298502Citation Count: 8
-
OPENTitle: White matter hyperintensities mediate the impact of amyloid ß on future freezing of gait in Parkinson's diseaseJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 85Issue #:Start Page: 95End Page: 101Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.02.031Citation Count: 14
-
OPENTitle: Effects of angiotensin type 1 receptor antagonists on Parkinson's disease progression: An exploratory study in the PPMI databaseJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 86Issue #:Start Page: 34End Page: 37Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.03.007Best OA location URL: https://repositorio.uca.edu.ar/handle/123456789/11625Citation Count: 12
-
OPENTitle: Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO studyJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 83Issue #:Start Page: 79End Page: 85Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.12.024Best OA location URL: http://www.prd-journal.com/article/S135380202100016X/pdfCitation Count: 66
-
OPENTitle: Duration of benefit per Dose: Carbidopa-Levodopa immediate release vs. extended release capsules (Rytary®)Journal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 82Issue #:Start Page: 133End Page: 137Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.12.002Best OA location URL: http://www.prd-journal.com/article/S1353802020309007/pdfCitation Count: 5
-
OPENTitle: Preserved motor memory in Parkinson's diseaseJournal Name: NeuropsychologiaPublisher: Elsevier BVVol: 167Issue #:Start Page: 108161End Page: 108161Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.neuropsychologia.2022.108161Citation Count: 13
-
OPENTitle: Removal of proteinase K resistant αSyn species does not correlate with cell survival in a virus vector-based Parkinson's disease mouse modelJournal Name: NeuropharmacologyPublisher: Elsevier BVVol: 218Issue #:Start Page: 109213End Page: 109213Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.neuropharm.2022.109213Best OA location URL: https://doi.org/10.1016/j.neuropharm.2022.109213Citation Count: 9
-
OPENTitle: Special Issue on new therapeutic approaches to Parkinson diseaseJournal Name: NeuropharmacologyPublisher: Elsevier BVVol: 208Issue #:Start Page: 108998End Page: 108998Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.neuropharm.2022.108998Citation Count: 5